Roche Presents New Data Demonstrating Potential Benefit Of Two Lymphoma Candidates

  • Roche Holdings AG RHHBY announced that updated clinical data for its CD20xCD3 T-cell engaging bispecific antibodies, including five oral presentations, were presented at the American Society of Hematology Annual Meeting & Exposition.
  • Updated data from the pivotal phase 2 NP30179 study in relapsed or refractory large B-cell lymphoma (R/R LBCL) showed glofitamab given as a fixed course induced early and durable responses that were maintained beyond the end of treatment. 
  • Most patients who had achieved a complete response experienced durable responses, with a median CR follow-up from the end of treatment of 11.5 months. 
  • Twelve months after the end of treatment with glofitamab, 61% of patients maintained a CR, 92.6% remained progression-free, and only one patient (n=1/44) experienced disease progression.
  • An updated analysis from the pivotal phase 2 GO29781 study of Lunsumio in people with R/R follicular lymphoma FL who had received two or more prior therapies showed that 60.0% achieved a CR and 77.8% achieved an objective response at a median follow-up of 28.3 months. 
  • After 24 months of achieving a CR, 62.7% of patients remained in remission. Overall, 48.3% of patients remained progression-free. 
  • Price Action: RHHBY shares are down 0.27% at $40.41 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!